Summary Marketline's Sunshine Heart Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Sunshine Heart Inc since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic...
GI Dynamics (GID) is preparing to commence a pivotal US clinical study for EndoBarrier, which remains to our knowledge the only implant targeted for treatment of type 2 diabetes mellitus (T2DM) plus obesity. GID would need to capture only a small share of a vast patient pool (up to 30m patients in the US alone) to achieve significant commercial potential. EndoBarrier is less invasive, less risky than gastric bypass surgery and combined with diabetes medication offers disease-modifying benefits...
Summary Marketline's Osprey Medical Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Osprey Medical Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organi...
GI Dynamics, Inc. ('GID') is a Boston US-based company focused on developing EndoBarrier. EndoBarrier is a unique medical device that provides a minimally invasive, reversible treatment option for subjects with type 2 diabetes mellitus (T2DM) and obesity, who are unable to control their disease using standard treatments alone. GID would need to capture only a small share of a vast patient pool (up to 30m patients in the US alone) to achieve significant commercial potential. EndoBarrier is the...
BOSTON & SYDNEY--(BUSINESS WIRE)-- GI Dynamics® Inc. (ASX: GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the meta-analysis, “Effects of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Type 2 Diabetic Patients with Obesity: A Meta-analysis with Secondary Analysis on Weight Loss and Hormonal Changes,” by Pichamol Jirapinyo, MD, of Brigham and Women’s Hospital in Boston, Massachusetts, and Diplomat of the American Board of Obesity Medic...
BOSTON & SYDNEY--(BUSINESS WIRE)-- GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® is pleased to announce that it has received binding commitments for a private placement of 58,780,619 CHESS Depositary Interests (CDIs) of the Company (representing 1,175,612 shares of common stock) at an issue price of AUD $0.035 per CDI to sophisticated and professional investors in Australia, the United States, and the United Kingdom to raise approximately AUD $2.05 million (representing approximately USD $1.6 m...
BOSTON & SYDNEY--(BUSINESS WIRE)-- GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® provides shareholders with a review of 2017 activities and its 2018 business outlook. GI Dynamics is preparing to submit an Investigational Device Exemption (IDE1) application to the US Food and Drug Administration (FDA) for a new pivotal trial of the EndoBarrier. In addition, GI Dynamics is focused on taking all appropriate measures to address the withdrawal of the EndoBarrier CE Certificate of Conformity...
BOSTON & SYDNEY--(BUSINESS WIRE)-- GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America, announces today that the board of directors has received the resignation of GI Dynamics non-executive directors Anne Keating and Graham Bradley. Both Keating and Bradley joined the GI Dynamics board of directors in 2011. “I very strongly believe in our mission to commercialize EndoBarrier, providing a solution to the unmet global need of su...
BOSTON & SYDNEY--(BUSINESS WIRE)-- GI Dynamics® Inc. (ASX: GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces it will provide a corporate update and discuss 2017 third quarter results to investors. The company will host a webcast at 4 PM EST 21 November 2017 | 8 AM AEDT 22 November 2017. Accessing the Webcast: The webcast may be accessed by clicking here or on the GI Dynamics w...
BOSTON & SYDNEY--(BUSINESS WIRE)-- GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America has received notification from its notified body SGS United Kingdom, Limited (SGS) that SGS will withdraw the CE Certificate of Conformity for EndoBarrier effective 12 November 2017. As previously announced, on 17 May 2017 the company received notification from SGS that the EndoBarrier CE Certificate of Conformity was being suspended pending resoluti...
LISBON, Portugal--(BUSINESS WIRE)-- GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces that new data has been released from the Institute for Clinical and Experimental Medications (“IK+EM”) on the comparison of 40 patients who underwent either gastric plication or EndoBarrier treatment or were control patients. The IK+EM released the data at the 53rd Annual Meeting of the European Association f...
BOSTON & SYDNEY--(BUSINESS WIRE)-- GI Dynamics® Inc. (ASX:GID), a medical device company that commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity announces the appointment of medical and financial markets veteran Juliet Thompson to the company’s board of directors, effective immediately. Thompson has assumed the role of non-executive director (NED) and the role of chair of the GI Dynamics audit committee. Graham Bradley, former chair of the audit commit...
BOSTON & SYDNEY--(BUSINESS WIRE)-- GI Dynamics® Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, welcomed new members to the GI Dynamics Scientific Advisory Board (SAB), bringing together distinguished physicians and scientists specializing in endocrinology, gastroenterology and bariatric/metabolic surgery. Gerald Holtmann, MD, and Thomas Rösch, MD, have joined the GI Dynamics SAB. The GI Dyna...
BOSTON & SYDNEY--(BUSINESS WIRE)-- GI Dynamics® Inc. (ASX: GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces it will update investors on 2017 second quarter results as reported on Form 10Q for the period ended June 30, 2017. The company will host a webcast at 6 pm EDT 14 August 2017 | 8 am AEST 15 August 2017. Accessing the Webcast: The webcast may be accessed by clicking here ...
BOSTON & SYDNEY--(BUSINESS WIRE)-- GI Dynamics® Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, today announced the selection of Proven Process Medical Devices, Inc. (PPMD) as its contract manufacturing partner. PPMD is one of the nation’s leading designers and manufacturers of Class II and Class III medical devices. The company was founded in 1994 to address the unmet need for an outsource provider to the...
BOSTON & SYDNEY--(BUSINESS WIRE)-- GI Dynamics® Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity announced additional members of the GI Dynamics Scientific Advisory Board (SAB), bringing together distinguished physicians and scientists specializing in endocrinology, gastroenterology and bariatric/metabolic surgery. Francesco Rubino, MD, and Philip Schauer, MD have joined the GI Dynamics SAB. Th...
BOSTON & SYDNEY--(BUSINESS WIRE)-- GI Dynamics® Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity today announced a US $5,000,000 convertible note financing. GI Dynamics conducted the financing solely with its major shareholder, Crystal Amber Fund Limited. The financing is intended to provide GI Dynamics with adequate working capital through the remainder of 2017. The key terms of the financing are o...
BOSTON & SYDNEY--(BUSINESS WIRE)-- GI Dynamics®, Inc., (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe for patients with type 2 diabetes and obesity, today announced data from a UK National Health Service (NHS) EndoBarrier Registry presented at the American Diabetes Association’s 77th Scientific Sessions demonstrated that metabolic improvements made by patients while implanted with EndoBarrier were sustained six months after EndoBarrier was explanted. The poster presentation, “Mainten...
BOSTON & HAMBURG--(BUSINESS WIRE)-- GI Dynamics® Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East, and South America for patients with type 2 diabetes and obesity brought forward data from an investigator-initiated study presented at the German Diabetes Congress 2017 in Hamburg, Germany. Initial data was introduced that examined the safety and efficacy of EndoBarrier re-implantation for the treatment of patients with type 2 diabetes and obesity. The observational ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.